PTC anticipates total revenues for the full-year 2024 to be between $600 million and $850 million. PTC anticipates GAAP R&D and SG&A expense for the full-year 2024 to be between $740 and $835 million. PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2024 to be between $660 and $755 million, including expected R&D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million. PTC anticipates up to $90 million of payments for the full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&D operating expense.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PTCT:
- Amgen upgraded, PepsiCo downgraded: Wall Street’s top analyst calls
- PTC Therapeutics downgraded to Underweight at Morgan Stanley
- PTC Therapeutics initiated with an Overweight at Wells Fargo
- PTC Therapeutics initiated with bullish view at Wells Fargo
- PTC Therapeutics provides regulatory update for Translarna in Europe, the U.S.
